Simply speaking, FCGR2/3 genetic variation may tip this balance to either side, leading to auto-immunity when the balance is tipped toward the activating side, or leading to decreased immunity against pathogens or cancer cells when the balance is tipped toward the inhibitory side. Here, FCGR2A is linked to cancer.